Long Term Follow-up Study for Subjects Administered CLBR001

Enrolling by invitation

Conditions studied: Long Term Follow-Up

In brief

The goal of this Long Term Follow-Up observational study is to monitor subjects who have received CLBR001, a lentiviral vector based chimeric antigen receptor, for delayed adverse events that may be associated with human gene therapies. Participants will be followed for 15 years post-gene therapy administration date for safety and efficacy.

Key facts

Study ID

NCT06882317

Run by

Calibr, a division of Scripps Research

People needed

40

Starts

2025-08-28

Expected to finish

2044-02-01

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who received at least one CLBR001 cell dose.

You may not qualify if…

• None

Where it is running

• Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States
• Virtual Research Group- Premier Research — Morrisville, North Carolina, United States
• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.